Marielle Chiron Selected Research

isatuximab

1/2022	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
1/2022	SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
12/2021	Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
1/2021	Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
12/2020	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
1/2020	In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.
1/2020	Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
9/2014	SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marielle Chiron Research Topics

Disease

10	Neoplasms (Cancer) 01/2022 - 03/2012
8	Multiple Myeloma 01/2022 - 09/2014
7	Colorectal Neoplasms (Colorectal Cancer) 07/2020 - 06/2014
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Thymoma (Thymic Carcinoma) 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Triple Negative Breast Neoplasms 07/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2014
1	Leukemia 09/2014
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 09/2014
1	Lymphoma (Lymphomas) 09/2014
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2014
1	Hematologic Neoplasms (Hematological Malignancy) 09/2014

Drug/Important Bio-Agent (IBA)

8	isatuximabIBA 01/2022 - 09/2014
7	afliberceptIBA 07/2020 - 06/2014
4	Monoclonal AntibodiesIBA 01/2022 - 01/2020
3	AntibodiesIBA 01/2022 - 11/2019
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2014
2	Biomarkers (Surrogate Marker)IBA 12/2021 - 11/2019
2	Dexamethasone (Maxidex)FDA LinkGeneric 12/2021 - 01/2021
2	LigandsIBA 01/2021 - 01/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 06/2014
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 09/2015
1	daratumumabIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	cemiplimabIBA 01/2022
1	pomalidomideIBA 12/2021
1	Lenalidomide (CC 5013)FDA Link 01/2021
1	iniparibIBA 07/2020
1	Pharmaceutical PreparationsIBA 07/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Chimeric Antigen ReceptorsIBA 01/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2020
1	Complement System Proteins (Complement)IBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2020
1	Bispecific AntibodiesIBA 01/2020
1	Fluorouracil (Carac)FDA LinkGeneric 11/2019
1	Kallikreins (Kallikrein)IBA 11/2019
1	Carrier Proteins (Binding Protein)IBA 11/2019
1	Irinotecan (Camptosar)FDA LinkGeneric 11/2019
1	Interleukin-8 (Interleukin 8)IBA 11/2019
1	Receptor for Advanced Glycation End ProductsIBA 11/2019
1	Insulin-Like Growth Factor Binding Protein 1IBA 11/2019
1	TenascinIBA 11/2019
1	Tissue Inhibitor of MetalloproteinasesIBA 11/2019
1	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 11/2019
1	Type II Tumor Necrosis Factor ReceptorsIBA 11/2019
1	Small Interfering RNA (siRNA)IBA 04/2016
1	Surface Antigens (Surface Antigen)IBA 09/2014
1	Bortezomib (Velcade)FDA Link 09/2014
1	Rituximab (Mabthera)FDA Link 09/2014
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2014
1	Bevacizumab (Avastin)FDA Link 06/2014
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 03/2012
1	Tetracycline (Achromycin)FDA LinkGeneric 03/2012

Therapy/Procedure

5	Therapeutics 01/2022 - 03/2012
2	Immunotherapy 01/2021 - 01/2020
1	Castration 01/2022
1	Organ Transplantation 11/2019
1	Injections 06/2014